Euroventures, headquartered in Budapest, Hungary, is one of the longest-established and leading independent private equity and venture capital firms in Central Europe, with a proven track record of international exits over two decades.
It’s advised/advising five investment programs totalling over EUR 180M since its establishment in 1989, with a focus on funding innovation and growth in Hungary and Central Europe.
Euroventures’ nearly 50 current and former portfolio companies illustrate the commitment to provide steady support through the cycles of the regional and global economy. Euroventures supports its partners’ growth with funding, advice and contacts, and has participated in some highly successful exits, incl. IPOs (Vienna, NASDAQ, NYSE), trade sales to international strategic investors and sales to management (e.g. EPAM’s IPO on NYSE and strategic sales of SequenceIQ, Medimass or IND Group).
Its professional team members have many decades of VC/PE experience. Investments have ranged from the milk industry and wine production to leading edge technologies in the fields of medtech, big data, security, and IoT among others, currently it targets innovative, growing companies seeking EUR 1-5M to fund technical development, investment and expansion.
Euroventures is a founding member of the Hungarian Venture Capital and Private Equity Association (HVCA).
Among its recent investments we can find the regenerative medicine R&D company OrthoSera or the Node.js developer and consultant company RisingStack.
More about Euroventures: http://www.euroventures.hu/en
